
PTHS Stock Forecast & Price Target
PTHS Analyst Ratings
Bulls say
Pelthos Therapeutics is poised for success with the recent launch of Zelsuvmi in the molluscum market, as the first approved at-home treatment option for this common pediatric skin infection. KOL feedback and early script trends suggest strong demand for Zelsuvmi, and we expect continued prescriber adoption and improved access to drive sales growth, reaching $275M at peak. With a sub-$250M market cap and a strong launch trajectory, Pelthos is an undervalued commercial execution story with potential for a significant valuation re-rating.
Bears say
Pelthos Therapeutics is a commercial-stage biopharmaceutical company with an expanding pipeline and FDA-approved assets, including Zelsuvmi, for the treatment of molluscum contagiosum. While Zelsuvmi's launch has been successful, it faces a paradox of a large market with low treatment penetration, and its impact on the company's overall financials will not be significant until 2026. The company's long IP runway provides room for potential growth, but its current financials may not justify its stock's high valuation.
This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PTHS Analyst Forecast & Price Prediction
Start investing in PTHS
Order type
Buy in
Order amount
Est. shares
0 shares